We have previously demonstrated a growth inhibitory effect of the small molecule STAT3 inhibitor galiellalactone as monotherapy in various prostate cancer models where STAT3 is constitutively activated in the tumor cells [21,22,23,24]. The gene discussed is STAT3; the disease is prostate cancer.